Ken Griffin Nymox Pharmaceutical Corp Transaction History

Citadel Advisors LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.19 - $0.49 $6,700 - $17,280	-35,266 Reduced 58.48%	25,040 $4,000
Q1 2023 May 15, 2023	SELL	$0.33 - $0.5 $7,873 - $11,929	-23,858 Reduced 28.35%	60,306 $20,000
Q4 2022 Feb 14, 2023	BUY	$0.28 - $0.74 $23,565 - $62,281	84,164 New	84,164 $26,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $1.41 $4,651 - $17,258	-12,240 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.21 - $2.0 $14,810 - $24,480	12,240 New	12,240 $15,000
Q3 2020 Nov 16, 2020	SELL	$2.3 - $3.66 $40,689 - $64,749	-17,691 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.1 - $4.6 $23,131 - $50,668	-11,015 Reduced 38.37%	17,691 $63,000
Q4 2019 Feb 14, 2020	BUY	$1.73 - $2.42 $27,235 - $38,098	15,743 Added 121.45%	28,706 $63,000
Q3 2019 Nov 14, 2019	SELL	$1.41 - $2.12 $14,919 - $22,431	-10,581 Reduced 44.94%	12,963 $23,000
Q1 2019 May 15, 2019	BUY	$1.57 - $2.71 $6,886 - $11,886	4,386 Added 22.89%	23,544 $0
Q4 2018 Feb 14, 2019	SELL	$1.31 - $2.53 $21,363 - $41,259	-16,308 Reduced 45.98%	19,158 $25,000
Q3 2018 Nov 13, 2018	SELL	$2.46 - $3.7 $44,917 - $67,558	-18,259 Reduced 33.99%	35,466 $0
Q2 2018 Aug 10, 2018	BUY	$3.12 - $4.33 $136,044 - $188,805	43,604 Added 430.83%	53,725 $0
Q1 2018 May 11, 2018	SELL	$3.09 - $4.43 $1,622 - $2,325	-525 Reduced 4.93%	10,121 $43,000
Q3 2017 Nov 09, 2017	BUY	$3.36 - $4.02 $35,770 - $42,796	10,646	10,646 $41,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.